AKBA Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Akebia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$2.48 |
| 52 Week Low | US$0.78 |
| Beta | 0.77 |
| 11 Month Change | 24.32% |
| 3 Month Change | 30.19% |
| 1 Year Change | 7.81% |
| 33 Year Change | -52.08% |
| 5 Year Change | -72.94% |
| Change since IPO | -94.83% |
Recent News & Updates
Recent updates
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Aug 02
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Shareholder Returns
| AKBA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | -2.8% | -2.7% |
| 1Y | 7.8% | 13.9% | 21.3% |
Return vs Industry: AKBA underperformed the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: AKBA underperformed the US Market which returned 21.3% over the past year.
Price Volatility
| AKBA volatility | |
|---|---|
| AKBA Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AKBA's share price has been volatile over the past 3 months.
Volatility Over Time: AKBA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 167 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Akebia Therapeutics, Inc. Fundamentals Summary
| AKBA fundamental statistics | |
|---|---|
| Market cap | US$293.35m |
| Earnings (TTM) | -US$40.44m |
| Revenue (TTM) | US$174.50m |
1.7x
P/S Ratio-7.2x
P/E RatioIs AKBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBA income statement (TTM) | |
|---|---|
| Revenue | US$174.50m |
| Cost of Revenue | US$30.90m |
| Gross Profit | US$143.60m |
| Other Expenses | US$184.04m |
| Earnings | -US$40.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 82.29% |
| Net Profit Margin | -23.18% |
| Debt/Equity Ratio | -276.0% |
How did AKBA perform over the long term?
See historical performance and comparison